Cystadenocarcinoma of the ovary: Features of treatment, prognosis and life expectancy

click fraud protection

Content

  • 1 Types and symptoms tsistadenokartsinoma
  • 2 stage
  • 3 methods of diagnosis
  • 4 Specific signs tsistadenokartsinoma
  • 5 Treatment and its effectiveness
  • 6 Serous and mucinous ovarian cystadenocarcinoma Forecast
  • 7 Life expectancy at cystadenocarcinoma of the ovary

ovarian cystadenocarcinoma ferriferous refers to the type of ovarian cancer glands. The tumor usually develops secondary to benign. With age, the risk of formation of Kantser increases. As with any form of cancer, cystadenocarcinoma has several stages of development. The prevalence of tumor cells, the degree of differentiation, the start of therapy are crucial to the survival prognosis of this disease.

Mucinous and serous papillary cystadenocarcinoma of the ovary

Types and symptoms tsistadenokartsinoma

Cystadenocarcinoma - a malignant disease originating from the epithelial structure of the ovary tissue. There are several types of tumors:

  • serous;
  • mucinous / pseudomucinous;
  • clear cell;
  • low-grade;
  • mixed.

Serous cystadenocarcinoma of the ovary is more common and is considered the most aggressive subtype of pathology. Malignant cells produce light serous fluid, hence the name of the carcinoma. Neoplasm occurs against a background of untreated benign growths, which are transformed into cancer. This tumor mainly affects both ovaries, is connected with what severity, speed of development disorders, early metastasis.

instagram viewer

Nizkodiferentsirovanny type carcinomas can be attributed to the late stage of the serous tumor. In this embodiment, the appearance of the cells is observed to determine the type of which is practically impossible. This indicates an extreme degree of malignancy of education: elements without specific tissue supplies are characterized by particularly rapid growth.

Clear-formation is extremely rare type of possessing the highest degree of malignancy. Are the least studied.

Mucinous cystadenocarcinoma of the ovary is less common. Tumor cells secrete a secret - or mucin psevdomutsin. The process is usually unilateral. The disease is slow, symptoms occur in the late stages, which significantly lowers the prognosis for the life of the patient.

Mucinous and serous papillary cystadenocarcinoma of the ovary

Key features of malignant transformation of ovarian tissue:

  • abdominal pain of varying intensity;
  • a feeling of heaviness, dyspepsia;
  • menstrual disorders;
  • frequent urination;
  • change in bowel function (constipation, bloating);
  • increase the volume of the stomach;
  • discomfort during sexual kontkatkah.

In the initial stages of the disease difficult to detect cancer - tsistadenokartsinoma long time no symptoms. In the future, there is a number of nonspecific complaints, indicating the presence of the disease. At this stage, you want to recognize the disease in time to begin treatment.

Symptomatology tumor depends on the degree of disease severity. Usually expressed signs of disorders testify about running processes.

Mucinous and serous papillary cystadenocarcinoma of the ovary

stage

Malignant tumors are classified into 4 stages:

  1. First degree adenocarcinoma tumor characterized by an arrangement exclusively in the redistribution of ovarian tissue and prostate capsule. Neoplasm usually does not manifest itself, it is a random finding during gynecological examination, ultrasound.
  2. In the second stage of Cancer grows in size, it is outside the body of the conversion stages. Cancerous elements found in the fallopian tubes, uterus, pelvic tissues in adjacent organs.
  3. Serous cystadenocarcinoma of the ovary Stage 3 is characterized by the proliferation of a pathological process beyond the pelvic peritoneum on the sheets or the lymph nodes.
  4. Regardless of the size of the primary tumor at 4 degree of disease found distant metastases outside the abdominal cavity.

Bilateral ovarian cystadenocarcinoma not affect the stage of the disease. When the diagnosis is crucial to the spread of cancer cells beyond the ovarian glands.

Mucinous and serous papillary cystadenocarcinoma of the ovary

methods of diagnosis

Suspected carcinoma of the ovary may be based on complaints and gynecological examination. High-grade serous ovarian cystadenocarcinoma one step is detected at a two-handed uterine study, when the doctor palpates the enlarged gland. Appendages with kantseromatoznym knot lumpy, painful.

To confirm the diagnosis of cystadenocarcinoma perform:

  • Pelvic ultrasound vascular doplerometrii;
  • CT / MRI;
  • a blood test for tumor markers;
  • a biopsy.

Ultrasound color Doppler mode (CFM) is considered the primary method of detecting ovarian Kantser. The study allows to visualize blood flow gonads, with high probability identify benign and malignant tumors.

The most accurate method of diagnosis, indicating the presence of abnormal cells tsistadenokartsinoma considered needle biopsy of the ovaries.

As additional studies to determine the staging appoint: radiography, FEGDS, colonoscopy.

Mucinous and serous papillary cystadenocarcinoma of the ovary

Specific signs tsistadenokartsinoma

Put ovarian tumor at an early stage of severe challenge. Pathology rarely exhibit strong to cause a woman's desire to address for consultation to the gynecologist. However suspected pathology reproductive sphere can be the appearance of menstrual disorders, general state of deterioration, pain during intercourse or exertion. There is a decrease of efficiency, lethargy, loss of appetite. A characteristic feature of late stage ovarian cancer is the waist volume increase due to accumulation of fluid in the abdominal cavity.

Changes in ovarian structure of the doctor discovers on the gynecological chair. During the inspection draws attention to the increase of the appendages, tuberosity, increasing density. In order to establish an accurate diagnosis is necessary instrumental methods. With manage hardware diagnostics on specific attributes to identify deviations from normal structure.

Specific characteristics that identify tsistadenokartsinomu ovaries in the early stages, do not exist.

Mucinous and serous papillary cystadenocarcinoma of the ovary

Treatment and its effectiveness

Therapy in ovarian cystadenocarcinoma mostly complex. It is used for surgery, chemotherapy and radiation technology. The particular approach depends on the process stage detection. The effectiveness of therapy depends on the process spread. Initiation of treatment in the early stages of development tsistadenokartsinoma has good results.

Tsistadenokartsinoma ovarian stage 3b relatively favorable prognosis. In this type of tumor can not perform a removal of all Kantser foci, however, preference is given combination chemotherapy and radiation therapy. Drug anticancer treatment is prescribed rates applied more often. Radiation correction used in rare cases of clear tsistadenokartsinom and mucinous types, which are difficult to himioterpii.

Unilateral excision of appendages shall be permitted only on the stage 1a of disease progression in type of highly differentiated structure of cancer cells in young women to preserve fertility.

Serous and mucinous ovarian cystadenocarcinoma Forecast

Tsistadenokartsinoma affect women of reproductive age. Extremely rare abnormality occurs in women after menopause.

Serous carcinoma is characterized by strong growth, early metastasis formation. The emergence of this type of tumor indicates poor prognosis. The earlier cancer is detected, the greater the likelihood of recovery.

The average five-year survival rate for ovarian cystadenocarcinoma is 35%.

Life expectancy at cystadenocarcinoma of the ovary

Ovarian tumor diseases require immediate treatment. The earlier diagnosed and treatment is started, the greater the chance of cure. Statistical year survival data are as follows:

  • Step 1 - 90%;
  • 2 -70%
  • 3 - 40%
  • and 4 comprise 17%.

Tsistadenokartsinoma secondary ovarian tumor, in order to prevent the development of which must be constantly observed by a gynecologist and remove benign growths ovarian glands.

The information and materials on this website are provided for informational purposes only. You should not rely on the information as a substitute for the actual professional medical advice, care or treatment.

  • Oct 21, 2019
  • 29
  • 286